Suitable for :

• Drug discovery biotech — companies using organoid models for target validation, phenotypic screening, and lead optimization.
• Organoid-based therapeutic developers — firms creating cell‑therapy or regenerative medicine products derived from organoids.
• High-content screening & analytics — companies offering imaging, AI, and bioinformatics pipelines to analyze organoid drug responses.